Suppr超能文献

[基线血浆前肾上腺髓质素中段水平对盐酸米多君治疗儿童体位性心动过速综合征长期预后的预测价值]

[Predictive value of baseline plasma midregional fragment of pro-adrenomedullin level on long-term outcome of postural tachycardia syndrome children treated with midodrine hydrochloride].

作者信息

Li Hongxia, Zhang Fengwen, Wang Yuli, Liu Ping, Zhang Chunyu, Feng Xueli, Du Junbao, Jin Hongfang

机构信息

Department of Pediatrics, Peking University First Hospital, Beijing 100034, China.

Department of Pediatrics, Peking University First Hospital, Beijing 100034, China; Email:

出版信息

Zhonghua Xin Xue Guan Bing Za Zhi. 2015 Jun;43(6):507-10.

Abstract

OBJECTIVE

To explore the predictive value of baseline plasma midregional fragment of pro-adrenomedullin level (MR-proADM) on long-term survival of postural tachycardia syndrome (POTS) children treated with midodrine hydrochloride.

METHODS

Fifty-three children (male 26, mean age (14.5 ± 4.5) years old) with POTS were included in this study, and all of them were diagnosed as POTS in our department from December 2007 to January 2010. Fifty-three children with POTS were divided into two groups according to the baseline plasma content of MR-proADM. Group I consisted of 35 POTS children with plasma content of MR-proADM > 61.5 ng/L, and the group II consisted of 18 POTS children with plasma content of MR-proADM ≤ 61.5 ng/L. The mean follow-up time was (67 ± 7) months. The orthostatic intolerance symptom score and the symptom free survival were compared between the 2 groups.

RESULTS

At the 60 months follow-up, the symptom score of children in group I was significantly lower than that in group II (χ(2) = 4.985, P < 0.05). At 72 months follow up, the symptom score was similar between the 2 groups (χ(2) = 0.004, P > 0.05) while the symptom free survival of group I was significantly higher than that in group II (χ(2) = 4.566, P < 0.05).

CONCLUSION

The baseline plasma MR-proADM level is value in predicting the long-term survival of POTS children treated with midodrine hydrochloride.

摘要

目的

探讨基线血浆肾上腺髓质素原中段水平(MR-proADM)对接受盐酸米多君治疗的体位性心动过速综合征(POTS)患儿长期生存的预测价值。

方法

本研究纳入53例POTS患儿(男26例,平均年龄(14.5±4.5)岁),所有患儿均于2007年12月至2010年1月在我科确诊为POTS。53例POTS患儿根据基线血浆MR-proADM含量分为两组。I组由35例血浆MR-proADM含量>61.5 ng/L的POTS患儿组成,II组由18例血浆MR-proADM含量≤61.5 ng/L的POTS患儿组成。平均随访时间为(67±7)个月。比较两组患儿的直立不耐受症状评分和无症状生存期。

结果

随访60个月时,I组患儿的症状评分显著低于II组(χ(2)=4.985,P<0.05)。随访72个月时,两组患儿的症状评分相似(χ(2)=0.004,P>0.05),而I组的无症状生存期显著高于II组(χ(2)=4.566,P<0.05)。

结论

基线血浆MR-proADM水平对预测接受盐酸米多君治疗的POTS患儿的长期生存具有价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验